Jordan M. Schecter

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

Jesús G. Berdeja, Deepu Madduri, Saad Z. Usmani et al. · The Lancet · 2021 · 1.5K citations

Hematological Malignancy, Cell Therapy, Immunotherapy +11

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

Antonio Palumbo, Asher Chanan‐Khan, Katja Weisel et al. · New England Journal of Medicine · 2016 · 1.5K citations · Full text

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Philippe Moreau, Michel Attal, Cyrille Hulin et al. · The Lancet · 2019 · 922 citations · Full text

Hematological Malignancy, Radiation Oncology, Medicine +9

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

Jesús F. San Miguel, Binod Dhakal, Kwee Yong et al. · New England Journal of Medicine · 2023 · 615 citations · Full text

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis

Efstathios Kastritis, Giovanni Palladini, Monique C. Minnema et al. · New England Journal of Medicine · 2021 · 609 citations · Full text